American Biotech Company Presents Data That Treats Hereditary Angioedema
Unprecedented HAE Attack Rate Reductions with ORLADEYO® (berotralstat): A Breakthrough in Medical Science.
BioCryst Pharmaceuticals, Inc., a leading American biotechnology company, has presented new real-world data that shows significant and sustained reductions in hereditary angioedema (HAE) attack rates after patients began treatment with ORLADEYO® (berotralstat). This groundbreaking development could have far-reaching implications for those suffering from this debilitating disease. $BioCryst Pharmaceuticals(BCRX.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
